Researchers in Japan have identified a surprising candidate for tackling one of Alzheimerโs diseaseโs most persistent biological features: the sticky protein clumps known as amyloid-beta.
A new study reports that oral doses of the amino acid arginineโalready widely used as a safe medication for other conditionsโcan disrupt these toxic aggregates in animals and may even reverse some of the resulting neurological damage.
Protein Build-up Dropped, Fewer Behavior Abnormalities
The team, led by neuroscientists at Kindai University and Japanโs National Institute of Neuroscience, tested arginine in male mice genetically engineered to develop Alzheimerโs-like amyloid-beta plaques. When the animals received arginine in their drinking water, the protein build-up in their brains dropped sharply.
The mice also showed fewer behavioral abnormalities and lower activity in genes linked to neuroinflammationโsuggesting that the treatment may be doing more than simply clearing deposits.
โOur study demonstrates that arginine can suppress amyloid-beta aggregation both in vitro and in vivo,โ said lead scientist Yoshitaka Nagai. โWhat makes this finding exciting is that arginine is already known to be clinically safe and inexpensive.โ
Alzheimer’s And Promising Step
The researchers also observed similar effects in fruit fly models, as well as in laboratory test-tube experiments. These results build on previous evidence that arginine can act as a โchemical chaperone,โ helping prevent misfolded proteins from sticking together. Importantly, earlier animal studies show that arginine can cross the blood-brain barrier, a major hurdle for most experimental Alzheimerโs drugs.
While the findings mark a promising step, experts caution that much more research is needed before considering human trials. The mice received relatively high doses of arginine, and scientists still do not know what levelโif anyโwould be safe or effective for people. There is also ongoing scientific debate over whether removing amyloid-beta plaques meaningfully slows or stops Alzheimerโs progression in humans.
Still, the study offers a tantalizing possibility: that a well-known, low-cost molecule might someday play a role in treating neurodegenerative diseases rooted in protein misfolding.
โGiven its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimerโs and potentially other related disorders,โ Nagai said. โOur findings open up new possibilities for developing arginine-based strategies for neurodegenerative diseases caused by protein aggregation.โ
About The Author
